StreetInsider.com News Articles

SELLAS Life Sciences enrolls first patient in phase 2 AML trial

Thu, 12 Mar 2026 08:44:38 -0400

SELLAS Life Sciences Group (NASDAQ: SLS) announced enrollment of the first patient in its Phase 2 trial evaluating SLS009 for newly diagnosed acute myeloid leukemia patients.

The randomized trial will enroll approximately 80 patients across two cohorts in the United States and Europe. The first cohort includes newly diagnosed patients unlikely to benefit from standard venetoclax/azacitidine therapy based on molecular profiling. The second cohort comprises patients who demonstrate confirmed lack of response after two treatment cycles of venetoclax/azacitidine.

SLS009, also known as tambiciclib, is a CDK9 inhibitor that targets patients with high unmet medical needs. The company plans to utilize predictive biomarker

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -
- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -
- Topline Data Expected in Q4 2026 –

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first patient has been enrolled in its randomized Phase 2 trial evaluating SLS009 (tambiciclib), a

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Thu, 12 Mar 2026 08:35:00 -0400

Form 8-K SELLAS Life Sciences For: Mar 11

Wed, 11 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260311/26146010.html

Form 8-K SELLAS Life Sciences For: Mar 11

Wed, 11 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260311/26146010.html

Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: Anson Funds Management LP

Tue, 17 Feb 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260217/26009064.html

Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: Anson Funds Management LP

Tue, 17 Feb 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260217/26009064.html

Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 30 Jan 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260130/25923709.html

Form SCHEDULE 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 30 Jan 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260130/25923709.html

SELLAS partners with IMPACT-AML for European SLS009 trial expansion

Wed, 14 Jan 2026 08:31:24 -0400

SELLAS Life Sciences Group Inc. (NASDAQ: SLS) announced it has entered an agreement with IMPACT-AML to conduct a clinical study evaluating SLS009 in Europe. The collaboration will provide access to multiple European clinical sites through IMPACT-AML's network.

IMPACT-AML is a pan-European project that connects patients, clinicians, and researchers to test AML therapies. The initiative is part of the EU Mission Cancer program and includes major research institutions such as IRST, the University of Bologna, and various European AML collaborative groups under the European Leukemia Net.

The European study plans to enroll approximately 40 patients to evaluate SLS009 in combination with azacitidine and

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe